Your browser doesn't support javascript.
loading
NK cell-mediated cytotoxicity contributes to tumor control by a cytostatic drug combination.
Ruscetti, Marcus; Leibold, Josef; Bott, Matthew J; Fennell, Myles; Kulick, Amanda; Salgado, Nelson R; Chen, Chi-Chao; Ho, Yu-Jui; Sanchez-Rivera, Francisco J; Feucht, Judith; Baslan, Timour; Tian, Sha; Chen, Hsuan-An; Romesser, Paul B; Poirier, John T; Rudin, Charles M; de Stanchina, Elisa; Manchado, Eusebio; Sherr, Charles J; Lowe, Scott W.
Afiliación
  • Ruscetti M; Department of Cancer Biology and Genetics, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Leibold J; Department of Cancer Biology and Genetics, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Bott MJ; Department of Cancer Biology and Genetics, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Fennell M; Department of Cancer Biology and Genetics, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Kulick A; Department of Molecular Pharmacology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Salgado NR; Department of Cancer Biology and Genetics, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Chen CC; Department of Cancer Biology and Genetics, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Ho YJ; Department of Cancer Biology and Genetics, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Sanchez-Rivera FJ; Department of Cancer Biology and Genetics, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Feucht J; Center for Cell Engineering and Immunology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Baslan T; Department of Cancer Biology and Genetics, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Tian S; Department of Cancer Biology and Genetics, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Chen HA; Department of Cancer Biology and Genetics, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Romesser PB; Department of Cancer Biology and Genetics, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Poirier JT; Department of Molecular Pharmacology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Rudin CM; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • de Stanchina E; Department of Molecular Pharmacology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Manchado E; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Sherr CJ; Department of Molecular Pharmacology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Lowe SW; Department of Cancer Biology and Genetics, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Science ; 362(6421): 1416-1422, 2018 12 21.
Article en En | MEDLINE | ID: mdl-30573629
ABSTRACT
Molecularly targeted therapies aim to obstruct cell autonomous programs required for tumor growth. We show that mitogen-activated protein kinase (MAPK) and cyclin-dependent kinase 4/6 inhibitors act in combination to suppress the proliferation of KRAS-mutant lung cancer cells while simultaneously provoking a natural killer (NK) cell surveillance program leading to tumor cell death. The drug combination, but neither agent alone, promotes retinoblastoma (RB) protein-mediated cellular senescence and activation of the immunomodulatory senescence-associated secretory phenotype (SASP). SASP components tumor necrosis factor-α and intercellular adhesion molecule-1 are required for NK cell surveillance of drug-treated tumor cells, which contributes to tumor regressions and prolonged survival in a KRAS-mutant lung cancer mouse model. Therefore, molecularly targeted agents capable of inducing senescence can produce tumor control through non-cell autonomous mechanisms involving NK cell surveillance.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Células Asesinas Naturales / Protocolos de Quimioterapia Combinada Antineoplásica / Citotoxicidad Inmunológica / Quinasa 4 Dependiente de la Ciclina / Quinasa 6 Dependiente de la Ciclina / Citostáticos / Vigilancia Inmunológica / Neoplasias Pulmonares Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Science Año: 2018 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Células Asesinas Naturales / Protocolos de Quimioterapia Combinada Antineoplásica / Citotoxicidad Inmunológica / Quinasa 4 Dependiente de la Ciclina / Quinasa 6 Dependiente de la Ciclina / Citostáticos / Vigilancia Inmunológica / Neoplasias Pulmonares Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Science Año: 2018 Tipo del documento: Article País de afiliación: Estados Unidos